Medication info
Rinawon Duo Tablet 2.5/500 mg (Linagliptin, Metformin)

Rinawon Duo Tablet 2.5/500 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Bright yellow, oval, biconvex, film-coated tablet.
Packaging
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201903534 · Approved 2019.05.29 · Insurance code 657808120

Summary

Main use
Improves blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should take as the initial dose the same doses of linagliptin and metformin that they were previously taking. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s previous metformin dose. When this drug is administered in combination with insulin, the insulin dose may need to be reduced to lower the risk of hypoglycemia (see Precautions, 3. Administration with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this drug because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in type 2 diabetes mellitus

View approved original text

This medication is prescribed to assist with blood sugar control in patients with type 2 diabetes by combining linagliptin and metformin. It helps manage blood sugar levels effectively when used in conjunction with dietary and exercise therapies. As a result, blood sugar levels are maintained steadily, greatly aiding diabetes management. This drug enhances the overall ability of patients to control their blood sugar.

How to take

Adult dose

The dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this drug 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should take as the initial dose the same doses of linagliptin and metformin that they were previously taking. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s previous metformin dose. When this drug is administered in combination with insulin, the insulin dose may need to be reduced to lower the risk of hypoglycemia (see Precautions, 3. Administration with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this drug because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).

Precautions

This medication contains two components that help control blood sugar. However, it can cause a serious side effect called lactic acidosis, thus it should not be used in patients with impaired kidney or liver function. Furthermore, this medication should not be administered to patients with type 1 diabetes, pregnant women, or those with severe heart disease. During treatment, symptoms of hypoglycemia may occur, especially when used concomitantly with insulin or sulfonylurea medications; therefore, blood sugar levels should be monitored carefully. Elderly patients with reduced kidney function or those taking other medications that may affect kidney function should undergo regular blood tests to monitor kidney status. This drug may cause side effects such as gastrointestinal disturbances, skin rashes, pancreatitis, arthralgia, and rarely, blistering dermatosis, so you should consult a doctor immediately if symptoms occur. In situations that can affect kidney function, such as surgery or radiological tests, this medication should be temporarily discontinued, and it can be resumed after kidney function has recovered. Pregnant or nursing women should avoid using this medication, and it is not recommended for use in children and adolescents. During treatment, it is advisable to avoid excessive alcohol intake, and caution is required when nutritional status is poor or dehydration is present. While drug interactions are relatively few, consultation with a doctor is recommended for potential dose adjustments when used with specific medications. Lastly, this medication should be stored out of reach of children and kept away from moisture.

Side effects

  • lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disturbances
  • cough
  • decreased appetite
Show 87 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid-like eruptions
  • severe arthralgia with disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disturbances
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • dermatological lesions
  • metastasis to the liver
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • anxiety
  • mood disorders
  • insomnia
  • depression
  • contusion
  • bone bruise
  • concussion
  • bone fracture
  • hand fracture
  • pruritus
  • hypertension
  • benign prostatic hyperplasia
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • confused state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture and should be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius. Proper storage helps preserve the efficacy and safety of the medication.

Appearance and packaging

Appearance

Bright yellow, oval, biconvex, film-coated tablet.

Package unit

30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.